Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy

This study sought to determine outcomes for patients with metastatic breast cancer (MBC) with no evidence of disease (NED) after treatment and to identify factors predictive of outcomes once the status of NED was attained.

[1]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? , 2010, Journal of the National Cancer Institute.

[2]  G. Hortobagyi.  Can we cure limited metastatic breast cancer? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Vincent-Salomon,et al.  Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study , 2010, The oncologist.

[4]  B. Kiely,et al.  Survival times of women with metastatic breast cancer starting first‐line chemotherapy in routine clinical practice versus contemporary randomised trials , 2013, Internal medicine journal.

[5]  J. Thomalla,et al.  Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors , 2014, SpringerPlus.

[6]  Mauro D'Amico,et al.  Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B. Kiely,et al.  How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Riccardi,et al.  Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians , 2013, Therapeutic advances in medical oncology.

[9]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Terry L. Smith,et al.  Is breast cancer survival improving? , 2004, Cancer.

[11]  G. Hortobagyi,et al.  Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED) , 1979, Journal of surgical oncology.

[12]  J. O'fallon,et al.  Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. , 1979, JAMA.

[13]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[14]  Terry L. Smith,et al.  Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy , 1999, Cancer.

[15]  S. Payne,et al.  Advanced cancer patients’ prognostic information preferences: a review , 2009, Palliative medicine.

[16]  G. Hortobagyi,et al.  Survival differences among women with de novo stage IV and relapsed breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[18]  R. Gelman,et al.  Survival of premenopausal women with metastatic breast cancer. Long‐term follow‐up of eastern cooperative group and cancer and leukemia group B studies , 1990, Cancer.

[19]  Kristine Broglio,et al.  Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Ueno,et al.  Improvement of survival and prospect of cure in patients with metastatic breast cancer , 2012, Breast Cancer.

[21]  Phyllis N Butow,et al.  Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.